View in EDS HTML Full Text PDF Full Text

Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.

Saved in:
Bibliographic Details
Title: Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.
Authors: Dong, Nana (AUTHOR), Ali-Khiavi, Payam (AUTHOR), Ghavamikia, Nima (AUTHOR), Pakmehr, SeyedAbbas (AUTHOR), Sotoudegan, Farzaneh (AUTHOR), Hjazi, Ahmed (AUTHOR), Gargari, Morad Kohandel (AUTHOR), Gargari, Homa Kohandel (AUTHOR), Behnamrad, Parisa (AUTHOR), Rajabi, Mohammadreza (AUTHOR), Elhami, Anis (AUTHOR), Saffarfar, Hossein (AUTHOR), Nourizadeh, Mehrdad (AUTHOR)
Source: Neurological Sciences. Apr2025, Vol. 46 Issue 4, p1489-1507. 19p.
Subjects: Blood-brain barrier disorders, Alzheimer's disease, Targeted drug delivery, Biomedical engineering, Drug stability
Abstract: Alzheimer's disease (AD) remains a formidable challenge in the field of neurodegenerative disorders, necessitating innovative therapeutic strategies. Nanomedicine, leveraging nanomaterials, has emerged as a promising avenue for AD treatment, with a key emphasis on overcoming the blood-brain barrier (BBB) to enhance drug delivery efficiency. This review provides a comprehensive analysis of recent advancements in the application of nanomaterials for AD therapy, highlighting their unique properties and functions. The blood-brain barrier, a complex physiological barrier, poses a significant hurdle for traditional drug delivery to the brain. Nanomedicine addresses this challenge by utilizing various nanomaterials such as liposomes, polymeric nanoparticles, and metal nanoparticles. These nanocarriers enable improved drug bioavailability, sustained release, and targeted delivery to specific brain regions affected by AD pathology. The review discusses the diverse range of nanomaterials employed in AD treatment, exploring their capacity to encapsulate therapeutic agents, modulate drug release kinetics, and enhance drug stability. Additionally, the multifunctionality of nanomaterials allows for simultaneous imaging and therapy, facilitating early diagnosis and intervention. Key aspects covered include the interaction of nanomaterials with Aβ aggregates, the role of antioxidants in mitigating oxidative stress, and the potential of nanomedicine in alleviating neuroinflammation associated with AD. Furthermore, the safety, biocompatibility, and toxicity profiles of various nanomaterials are scrutinized to ensure their clinical applicability. In conclusion, this review underscores the pivotal role of nanomedicine and nanomaterials in revolutionizing AD treatment strategies. By specifically addressing BBB challenges, these innovative approaches offer new avenues for targeted drug delivery and improved therapeutic outcomes in the complex landscape of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 183814374
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Dong%2C+Nana%22">Dong, Nana</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ali-Khiavi%2C+Payam%22">Ali-Khiavi, Payam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ghavamikia%2C+Nima%22">Ghavamikia, Nima</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pakmehr%2C+SeyedAbbas%22">Pakmehr, SeyedAbbas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sotoudegan%2C+Farzaneh%22">Sotoudegan, Farzaneh</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hjazi%2C+Ahmed%22">Hjazi, Ahmed</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gargari%2C+Morad+Kohandel%22">Gargari, Morad Kohandel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gargari%2C+Homa+Kohandel%22">Gargari, Homa Kohandel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Behnamrad%2C+Parisa%22">Behnamrad, Parisa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rajabi%2C+Mohammadreza%22">Rajabi, Mohammadreza</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Elhami%2C+Anis%22">Elhami, Anis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saffarfar%2C+Hossein%22">Saffarfar, Hossein</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nourizadeh%2C+Mehrdad%22">Nourizadeh, Mehrdad</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Apr2025, Vol. 46 Issue 4, p1489-1507. 19p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Blood-brain+barrier+disorders%22">Blood-brain barrier disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Targeted+drug+delivery%22">Targeted drug delivery</searchLink><br /><searchLink fieldCode="DE" term="%22Biomedical+engineering%22">Biomedical engineering</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+stability%22">Drug stability</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Alzheimer's disease (AD) remains a formidable challenge in the field of neurodegenerative disorders, necessitating innovative therapeutic strategies. Nanomedicine, leveraging nanomaterials, has emerged as a promising avenue for AD treatment, with a key emphasis on overcoming the blood-brain barrier (BBB) to enhance drug delivery efficiency. This review provides a comprehensive analysis of recent advancements in the application of nanomaterials for AD therapy, highlighting their unique properties and functions. The blood-brain barrier, a complex physiological barrier, poses a significant hurdle for traditional drug delivery to the brain. Nanomedicine addresses this challenge by utilizing various nanomaterials such as liposomes, polymeric nanoparticles, and metal nanoparticles. These nanocarriers enable improved drug bioavailability, sustained release, and targeted delivery to specific brain regions affected by AD pathology. The review discusses the diverse range of nanomaterials employed in AD treatment, exploring their capacity to encapsulate therapeutic agents, modulate drug release kinetics, and enhance drug stability. Additionally, the multifunctionality of nanomaterials allows for simultaneous imaging and therapy, facilitating early diagnosis and intervention. Key aspects covered include the interaction of nanomaterials with Aβ aggregates, the role of antioxidants in mitigating oxidative stress, and the potential of nanomedicine in alleviating neuroinflammation associated with AD. Furthermore, the safety, biocompatibility, and toxicity profiles of various nanomaterials are scrutinized to ensure their clinical applicability. In conclusion, this review underscores the pivotal role of nanomedicine and nanomaterials in revolutionizing AD treatment strategies. By specifically addressing BBB challenges, these innovative approaches offer new avenues for targeted drug delivery and improved therapeutic outcomes in the complex landscape of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=183814374
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-024-07871-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 19
        StartPage: 1489
    Subjects:
      – SubjectFull: Blood-brain barrier disorders
        Type: general
      – SubjectFull: Alzheimer's disease
        Type: general
      – SubjectFull: Targeted drug delivery
        Type: general
      – SubjectFull: Biomedical engineering
        Type: general
      – SubjectFull: Drug stability
        Type: general
    Titles:
      – TitleFull: Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dong, Nana
      – PersonEntity:
          Name:
            NameFull: Ali-Khiavi, Payam
      – PersonEntity:
          Name:
            NameFull: Ghavamikia, Nima
      – PersonEntity:
          Name:
            NameFull: Pakmehr, SeyedAbbas
      – PersonEntity:
          Name:
            NameFull: Sotoudegan, Farzaneh
      – PersonEntity:
          Name:
            NameFull: Hjazi, Ahmed
      – PersonEntity:
          Name:
            NameFull: Gargari, Morad Kohandel
      – PersonEntity:
          Name:
            NameFull: Gargari, Homa Kohandel
      – PersonEntity:
          Name:
            NameFull: Behnamrad, Parisa
      – PersonEntity:
          Name:
            NameFull: Rajabi, Mohammadreza
      – PersonEntity:
          Name:
            NameFull: Elhami, Anis
      – PersonEntity:
          Name:
            NameFull: Saffarfar, Hossein
      – PersonEntity:
          Name:
            NameFull: Nourizadeh, Mehrdad
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1